JP2025510606A5 - - Google Patents

Info

Publication number
JP2025510606A5
JP2025510606A5 JP2024554214A JP2024554214A JP2025510606A5 JP 2025510606 A5 JP2025510606 A5 JP 2025510606A5 JP 2024554214 A JP2024554214 A JP 2024554214A JP 2024554214 A JP2024554214 A JP 2024554214A JP 2025510606 A5 JP2025510606 A5 JP 2025510606A5
Authority
JP
Japan
Prior art keywords
antibody
drug conjugate
pharmaceutically acceptable
conjugate according
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024554214A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025510606A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2023/085097 external-priority patent/WO2023186015A1/zh
Publication of JP2025510606A publication Critical patent/JP2025510606A/ja
Publication of JP2025510606A5 publication Critical patent/JP2025510606A5/ja
Pending legal-status Critical Current

Links

JP2024554214A 2022-03-30 2023-03-30 B7h4抗体薬物複合体及びその使用 Pending JP2025510606A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202210334522.X 2022-03-30
CN202210334522 2022-03-30
PCT/CN2023/085097 WO2023186015A1 (zh) 2022-03-30 2023-03-30 B7h4抗体药物偶联物及其用途

Publications (2)

Publication Number Publication Date
JP2025510606A JP2025510606A (ja) 2025-04-15
JP2025510606A5 true JP2025510606A5 (cg-RX-API-DMAC10.html) 2026-04-01

Family

ID=88199403

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024554214A Pending JP2025510606A (ja) 2022-03-30 2023-03-30 B7h4抗体薬物複合体及びその使用

Country Status (13)

Country Link
US (1) US20250032630A1 (cg-RX-API-DMAC10.html)
EP (1) EP4501363A1 (cg-RX-API-DMAC10.html)
JP (1) JP2025510606A (cg-RX-API-DMAC10.html)
KR (1) KR20240163098A (cg-RX-API-DMAC10.html)
CN (1) CN118922210A (cg-RX-API-DMAC10.html)
AU (1) AU2023245347A1 (cg-RX-API-DMAC10.html)
CA (1) CA3245849A1 (cg-RX-API-DMAC10.html)
CL (1) CL2024002903A1 (cg-RX-API-DMAC10.html)
CO (1) CO2024013243A2 (cg-RX-API-DMAC10.html)
IL (1) IL315698A (cg-RX-API-DMAC10.html)
MX (1) MX2024011866A (cg-RX-API-DMAC10.html)
TW (2) TW202340255A (cg-RX-API-DMAC10.html)
WO (1) WO2023186015A1 (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250079213A (ko) 2022-10-09 2025-06-04 라노바 메디신즈 리미티드 화합물, 조성물 및 방법
IL320634A (en) * 2022-11-04 2025-07-01 Alx Oncology Inc EXATECAN derivatives and antibody-drug conjugates
EP4623936A1 (en) * 2022-11-22 2025-10-01 Keymed Biosciences (Chengdu) Co., Ltd. Fused ring compound, conjugate thereof and use thereof
CN122028937A (zh) * 2023-10-14 2026-05-12 上海翰森生物医药科技有限公司 癌症的抗体药物偶联物疗法
WO2025087264A1 (en) * 2023-10-23 2025-05-01 Hansoh Bio Llc Ligand-cytotoxicity drug conjugates and pharmaceutical uses thereof
AU2024380559A1 (en) 2023-11-17 2026-06-04 Mersana Therapeutics, Inc. Treatment of cancer using b7-h4-targeted antibody-drug conjugates
WO2025241867A1 (zh) * 2024-05-24 2025-11-27 明慧医药(杭州)有限公司 抗b7-h4抗体药物偶联物及其应用
WO2026151884A1 (en) 2025-01-09 2026-07-16 Mersana Therapeutics, Inc. Treatment of cancer using b7-h4-targeted antibody-drug conjugates

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US9676854B2 (en) 2011-08-15 2017-06-13 Medimmune, Llc Anti-B7-H4 antibodies and their uses
US9562099B2 (en) 2013-03-14 2017-02-07 Genentech, Inc. Anti-B7-H4 antibodies and immunoconjugates
TW201625689A (zh) * 2014-09-12 2016-07-16 建南德克公司 抗-b7-h4抗體及免疫結合物
BR112020015736A2 (pt) * 2018-02-11 2020-12-08 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Anticorpo anti-b7-h4, fragmento de ligação a antígeno do mesmo e uso farmacêutico do mesmo
AU2020288275A1 (en) * 2019-06-06 2022-02-03 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Anti-B7-H4 antibody–drug conjugate and medicinal use thereof
JP7726534B2 (ja) * 2020-06-30 2025-08-20 諾納生物(蘇州)有限公司 抗b7h4抗体及びその二重特異性抗体および用途

Similar Documents

Publication Publication Date Title
JP2024535637A5 (cg-RX-API-DMAC10.html)
JP2025503214A5 (cg-RX-API-DMAC10.html)
JP2023535598A5 (cg-RX-API-DMAC10.html)
JP2012522513A5 (cg-RX-API-DMAC10.html)
US8889130B2 (en) Treatment of osteoarthritis and pain
JP2019031565A5 (cg-RX-API-DMAC10.html)
EP3678700B1 (en) Compounds for reducing the viscosity of biological formulations
JP2012522512A5 (cg-RX-API-DMAC10.html)
JP2014139173A5 (cg-RX-API-DMAC10.html)
RU2011144119A (ru) АНТИТЕЛА К FcRH5, ИХ ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
JP2021527640A5 (cg-RX-API-DMAC10.html)
RU2014113304A (ru) Анти-cd40-антитела, применение и методы
JP2020509027A5 (cg-RX-API-DMAC10.html)
RU2011144141A (ru) АНТИТЕЛА К FcRH5, ИХ ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
JP2025516381A5 (cg-RX-API-DMAC10.html)
JP2022507781A5 (cg-RX-API-DMAC10.html)
JP2025503214A (ja) Her3抗体-薬物結合体及びその使用
AU2022316425A1 (en) Drug conjugate of eribulin derivative
JP2020534326A5 (cg-RX-API-DMAC10.html)
JPWO2023033129A5 (cg-RX-API-DMAC10.html)
JP2023552790A5 (cg-RX-API-DMAC10.html)
EP4525930A1 (en) Methods of treating cancer using anti-cd22 antibody oligonucleotide conjugates
JP2025508779A5 (cg-RX-API-DMAC10.html)
RU2016119491A (ru) Конъюгаты антитела к efna4 с лекарственным средством
KR20260054692A (ko) 항-b7-h3 항체 및 이의 용도